The content below is part of a paid sponsorship and is not an endorsement by the American Association for Cancer Research^® (AACR), nor does it reflect the views or opinions of the AACR or its members.

Inocras & Broad Institute – Cancer Genome Nexus: New Analysis of Whole-Cancer Genomes

The Cancer Genome Atlas (TCGA) has been pivotal in advancing our understanding of cancer genomics. While initial discoveries were based on whole-exome sequencing, the recent public release of high-quality whole-genome sequencing (WGS) data from nearly all tumor/normal pairs provides an unprecedented opportunity for additional, powerful insights into the disease.

Researchers at the Broad Institute and Inocras joined in a transformational cancer genome initiative to analyze >8,000 TCGA WGS tumor/normal paired samples, utilizing two advanced whole-genome bioinformatics pipelines developed by both organizations. Variant call data was consolidated into a single frozen dataset to enable a consistent analysis across both groups and robust benchmarking of computational and AI methods. The key insights from this extensive collaboration will be presented across various forums and poster sessions during the AACR Annual Meeting 2026:

• New Insights from TCGA Whole-Genome Sequencing
  Saturday, April 18th, 12:30 pm, Room 33 – Upper Level – Convention Center
  Educational Session chaired by Professor Getz
• TCGA and Beyond: Whole-Genome Data Powering the Next Era of Cancer Intelligence
  Monday, April 20th, 12:30 pm, Theater A
  Inocras and Broad teams will jointly present at the Exhibitor Spotlight session

The presentations will showcase new data that demonstrates how comprehensive whole-genome analytics significantly expand the variant landscape to improve driver gene discovery, and ultimately enable new, clinically actionable insights. The speakers will introduce Cancer Genome Nexus, the next collaborative initiative focused on scaling this standardized whole-genome framework to larger datasets.

Visit Inocras booth #3145 to learn more about the Cancer Genome Nexus initiative and get the complete list of posters related to the TCGA WGS analysis initiative.

Inocras is a bioinformatics-led company redefining precision health through whole genome data and proprietary analytics. The oncology and rare disease platforms integrate comprehensive whole-genome data with advanced automation to deliver curated and actionable insights at scale that accelerate discovery and diagnostics to improve patient care, bringing a real-world impact. Inocras operates a CLIA-certified, CAP-accredited laboratory and partners with leading hospitals, pharmaceutical companies, and research institutions worldwide.

For more information, please visit inocras.com or contact us at: [email protected]

---